ACE and COVID-19: When analyzing preexisting treatment with ACE inhibitors or ARBs among patients with moderate COVID-19 (n = 9) and COVID-19 in the ICU (n = 34), there was no significant difference in sACE2 levels in either group (Supplementary Figure 4).